TP53 and B-cell chronic lymphocytic leukemia: A phase III multicenter open-label trial (CLL16) will compare the addition of acalabrutinib to the combination of obinutuzumab and venetoclax in the first line for patients with high-risk CLL, defined as TP53 aberration or complex karyotype (NCT05197192).